IN THIS ISSUE

- COVID-19 Vaccine Acceptance
- *Mucuna pruriens* and Fertility
- Use of Personal Protective Equipment
- Post-Menopausal Haematological Profile
- Carotid Doppler Ultrasonography
- Diet, Physical Activity and Sleep patterns
- Spindle Cell Sarcomatoid Lung Cancer
- Post-abortion Uterine Inversion
ORIGINAL RESEARCH

Alterations in Haematological and Clotting Profile of Post-Menopausal Women in Benin City, Nigeria
Ebengho MI1,2, Obazelu PA1, Emokpae MA*1

1Department of Medical Laboratory Science, School of Basic Medical Sciences, University of Benin, Benin-City, Nigeria
2Department of Haematology and Blood Transfusion, University of Benin Teaching Hospital, Benin City, Nigeria

*Correspondence: Professor MA Emokpae, Department of Medical Laboratory Science, School of Basic Medical Sciences, University of Benin, Benin City, Edo State, Nigeria.
E-mail: mathias.emokpae@uniben.edu; ORCID – https://orcid.org/0000-0002-6266-1774.

Abstract

Background: The cessation of ovarian functions at menopause and the accompanying decline in the production of ovarian steroid hormones creates a unique set of health concerns for women. Reductions in sex steroid levels, particularly oestrogen, have been associated with various diseases and conditions, including bleeding disorders, coronary heart disease (CHD), osteoporosis, cognitive dysfunction, urinary incontinence, hot flushes, and mood changes, among others.

Objective: To determine changes in haemorheological and clotting profile in post-menopausal women.

Methods: Two hundred participants comprising one hundred and fifty post-menopausal women and fifty healthy pre-menopausal control subjects were studied. The investigations carried out include whole blood viscosity, plasma viscosity, fibrinogen concentration, Prothrombin time (PT), Activated partial thromboplastin time with kaolin (APTTK) levels and complete blood count using standard methods.

Results: The mean age (p = 0.01), platelet count (p = 0.013), neutrophil (p = 0.03), neutrophil to lymphocyte ratio (p = 0.045) and platelet to lymphocyte ratio (p = 0.044) in postmenopausal women were significantly higher while lymphocyte count (p = 0.004) was significantly lower in postmenopausal compared to premenopausal women. Similarly, plasma oestradiol (p = 0.001), plasma viscosity (p = 0.03), relative blood viscosity (p = 0.03), whole blood viscosity (p = 0.03) and PTTK (p = 0.04) were significantly lower among postmenopausal women compared to premenopausal control subjects.

Conclusion: Relative plasma viscosity correlated positively with age. There were significantly lower levels of haemorheological and clotting profile in post-menopausal women. These changes may be due to age or a decline in circulating oestrogen levels.

Keywords: Coagulation, Female, Menopause, Nigeria, Oestradiol, Plasma viscosity, Post-menopause.

Introduction

The moment in a woman's life following menopause is called post-menopause. A woman is post-menopausal when she has not had her menstruation for an entire year. [1] Menopausal symptoms, such as hot flashes, can cease for most women during this stage. [2, 3] Hormone
replacement therapy has been associated with lower rates of cardiovascular diseases in post-menopausal women. [4, 5] The underlying metabolic basis for the reduced vascular risk has been explained, in part, by favourable changes in low-density lipoprotein (LDL), high-density lipoprotein (HDL), and thrombotic markers such as plasminogen activator inhibitor, fibrinogen, and D-dimer. [6 - 8]

A few researchers have also reported changes in post-menopausal women's coagulation factors. The investigation of coagulation factors in post-menopausal women revealed that fibrinogen levels rise within six weeks of hormone replacement therapy (HRT), and antithrombin III levels fall, leading to a thrombogenic state. In another report, fibrinogen and LDL cholesterol, generally recognised risk markers of cardiovascular disease, were favourably influenced by raloxifene therapy on healthy post-menopausal women. [9] Furthermore, in investigating the effect of oestrogen-progesterone hormonal replacement therapy on blood coagulation and fibrinolysis in post-menopausal women, prothrombin time (PT) was low. The shortening of PT observed in post-menopausal women, and other study groups was attributed to the increase in factor VII. However, there was no observable change in activated partial thromboplastin time (APTT) and thrombin time (TT). [10]

Post-menopausal stage of life in women is associated with a low oestrogen level. Menopausal symptoms also accompany this decrease in oestrogen. Previous research has also reported that post-menopausal women are at increased risk of developing conditions like atherosclerosis, coronary heart disease, osteoporosis, and cancer. [11, 12] These conditions were more complicated in women who smoked cigarettes. [13] Despite these reports, there is a lack of information on the haemorheological changes and clotting profile of post-menopausal women in Nigeria. This study aimed to determine the changes in haemorheology and clotting profile in a cohort of post-menopausal Nigerian women.

**Methods**

This study was a cross-sectional survey of post-menopausal women conducted at the University of Benin Teaching Hospital, Benini City, Edo State, Nigeria, between June 2015 and April 2016. Ethical clearance for the study was obtained from the ethics committee of the Edo State Ministry of Health, Benin City, while informed consent was given by the participants before the commencement of the study. A semi-structured questionnaire was used to collect the socio-demographic and medical history of the participants. Two hundred participants were randomly recruited, comprising 150 post-menopausal women, aged 50 years and above and who had not menstruated for at least one year, without any chronic disease and not on oestrogen replacement therapy. Also, 50 apparently healthy pre-menopausal women, aged ≤40 years who were pre-menopausal and not on oestrogen-based contraceptives were recruited as controls. Full blood count, red cell indices, relative plasma viscosity, whole blood viscosity, fibrinogen, Prothrombin, and PTTK were determined while neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios were calculated.

**Inclusion and exclusion criteria**

Apparently healthy women who had natural menopause without any hormonal or surgical intervention and weighing 55–60 kg with a height of 150–160 cm were enrolled. Weight- and height matched women who were having regular menstruation were included as control subjects. The age of the controls was 30–40 years. Women with lifestyle habits such as tobacco chewing and smoking known to have diabetes mellitus and hypertension, surgically induced menopause or
history of coagulopathies, thyroid diseases, and those on medications known to affect the haematological and haemorrhheological values were excluded from the study.

**Blood sample collection**

Eight millilitres of blood were drawn from the participants in the morning hours. Three millilitres of the venous blood were dispensed in Ethylene diamine tetra-acetic acid (EDTA) containers with anticoagulant to blood ratio of 1:99 parts. Another 3mL of the blood was emptied into 0.33mL of 3.2% sodium citrate to determine partial thromboplastin time with kaolin (PTTK) and prothrombin time (PT). Also, 2mL of the blood was dispensed into a plain container, allowed to clot and separated to obtain serum used for oestradiol level assay by Enzyme-Linked Immunosorbent Assay (ELISA) technique. The full blood count, partial thromboplastin time with kaolin and prothrombin time were determined on the same day the blood samples were collected.

**Sample Analysis**

Full blood count was conducted using the automated ERMA Haematology auto analyser PCE-210N (Diamond Diagnostic; Holliston, USA). The partial thromboplastin time with kaolin (PTTK) and prothrombin time (PT) were assayed manually using reagents supplied by BIOLABS Diagnostics, Maizy, France.

**Partial Thromboplastin Time with Kaolin (PTTK)**

A 1:9 anticoagulant to blood ratio sample was collected into a clean container and centrifuged using the bucket centrifuge for 15 minutes at 1000g to obtain platelet-poor plasma. Plasma (0.1ml) was dispensed into a clean, dry glass test tube, 0.1ml of pre-warmed kaolin/platelet substitute aliquot was added to the test tube and incubated at 37°C in a water bath for two minutes. The sample was re-calified with 0.1ml of 0.025M calcium chloride. A stopwatch started immediately while tilting the tube back and forth within the water bath while observing for clot formation. At first sight of clot formation, the watch was stopped, and the result was recorded in seconds.

**Prothrombin time (PT)**

Citrated plasma (0.1ml) was dispensed into a test tube and incubated at 37°C for two minutes in a water bath. Pre-warmed thromboplastin/calcium chloride reagent (0.2ml) was added to the test tube using an automatic pipette. The stopwatch was started concurrently while tilting the tube in the water bath and examining for clot formation. At first sight of clot formation, the stopwatch was stopped, and the result was recorded in seconds.

**Whole Blood and Plasma Viscosity Measurements**

Whole blood and plasma viscosity were measured using a low-cost syringe method to measure relative plasma viscosity (RPV) and relative whole blood viscosity (RBV). Exactly 2ml of the whole blood sample was drawn using a syringe, and the syringe was fixed in a vertical position. The syringe's plunger was removed, and the blood was allowed to flow freely into a collection vessel. The flow of the blood was observed and timed using a stopwatch.

RBV was calculated using the following equation:

\[
RBV = \frac{t_{blood}}{t_{water}}
\]

Where \(t_{blood}\) = the time of flow of 2ml of whole blood.

\(t_{water}\) = the flow time of 2ml of distilled water (standard).

RPV was measured using a plasma sample with the same procedure described for WBV above.

The following equation calculated RPV:

\[
RPV = \frac{t_{plasma}}{t_{water}}
\]

Where \(t_{plasma}\) = the time of flow of 2ml of plasma

\(t_{water}\) = the flow time of 2ml of distilled water (standard).
Plasma Fibrinogen Determination

The plasma sample was diluted (1:10 dilution), and 200ul of each plasma dilution was dispensed into a test cuvette and incubated at 37°C for two minutes. A hundred microlitre of the room temperature fibrinogen reagent was added rapidly, and simultaneously the timer started. The clotting time was recorded in seconds, and all the samples were processed in duplicate. A standard curve was created by plotting the average clotting time against fibrinogen concentration on a log-log graph. The concentration (mg/dl) was on the x-axis and clotting time (sec) on the y-axis. The assigned fibrinogen value on the normal control was used to determine fibrinogen values for the dilution.

Results

Table I compares some haematological indices between post-menopausal and pre-menopausal women. The mean age (p = 0.001), platelet count (p = 0.013), neutrophil (p = 0.03), neutrophil to lymphocyte ratio (p = 0.044) were significantly higher in postmenopausal women, while the total lymphocyte count was significantly lower (p = 0.04) in postmenopausal than premenopausal women.

Table II shows that the mean serum oestradiol, plasma viscosity (PV), relative plasma viscosity (RPV), whole blood viscosity (WBV) and PTTK were significantly lower (p = 0.005) among post-menopausal women compared to pre-menopausal women. However, the difference in the mean prothrombin time (PT) and fibrinogen were not significant between post-menopausal and pre-menopausal women. Table III shows the correlation of haematological parameters with age. Only RPV correlated positively with age, while the correlation between the other measured indices and age were insignificant.

Discussion

Several changes occur in the physiological indices of post-menopausal women, and some of these are known to increase the risk of cardiovascular diseases such as stroke and ischemic heart disease. These alterations may include changes in fat distribution and metabolism and fibrinolytic activities. [16]
Table I: Comparison of selected haematological indices between post-menopausal and pre-menopausal women.

| Variables        | Post-menopausal Mean ± SEM (n= 100) | Pre-menopausal Mean ± SEM (n= 50) | P-value |
|------------------|-----------------------------------|-----------------------------------|---------|
| Age (Years)      | 54.70±0.30                        | 29.60±0.50                        | 0.000   |
| PCV (%)          | 39.90±0.50                        | 40.22±0.60                        | 0.494   |
| Hb conc. (g/dl)  | 12.27±0.20                        | 12.79±0.20                        | 0.144   |
| MCV (fl)         | 78.89±0.60                        | 81.10±1.00                        | 0.601   |
| MCH (pg)         | 23.56±0.40                        | 26.11±0.40                        | 0.966   |
| MCHC (g/dl)      | 29.58±0.20                        | 30.22±0.20                        | 0.271   |
| PLT (x10^9/l)    | 187.15±5.00                       | 159.8±7.00                        | 0.013   |
| TWBC (x10^9/l)   | 4.26±0.10                         | 4.68±0.20                         | 0.668   |
| Lymphocytes (%)  | 41.45±2.00                        | 49.94±2.00                        | 0.043   |
| Neutrophils (%)  | 44.59±2.00                        | 34.70±2.00                        | 0.035   |
| Monocytes (%)    | 13.74±0.50                        | 15.04±0.80                        | 0.115   |
| NLR              | 1.07 ±0.05                        | 0.83 ±0.01                        | 0.045   |
| PLR              | 4.51 ±0.10                        | 3.20 ±0.21                        | 0.044   |

PCV - Packed Cell Volume; Hb conc. – Haemoglobin concentration; MCV - Mean Cell Volume; MCHC - Mean Cell Haemoglobin Concentration; PLT - Platelet count; TWBC - Total White Blood Cell count; NLR - Neutrophil-to-lymphocyte ratio; PLR - Platelet-to-lymphocyte ratio.

Table II: Comparison of some serum oestradiol, some coagulation and haemorheological parameters between post-menopausal women and pre-menopausal women

| Variables        | Post-menopausal Mean ± SEM (n= 100) | Pre-menopausal Mean ± SEM (n= 50) | P-value |
|------------------|-----------------------------------|-----------------------------------|---------|
| Oestradiol (pg/ml) | 41±2.16                          | 265.2±4.6                         | 0.001   |
| PV (ml/min)      | 5.89±0.10                        | 7.35±0.30                         | 0.031   |
| RPV              | 2.72±0.07                        | 3.53±0.20                         | 0.032   |
| WBV (ml/min)     | 13.63±0.20                       | 41.14±2.00                        | 0.039   |
| PT (sec)         | 14.52±0.20                       | 15.72±1.00                        | 0.726   |
| PTTK (sec)       | 34.82±0.70                       | 37.32±2.00                        | 0.045   |
| Fibrinogen (g/l) | 4.36±0.10                        | 4.29±0.20                         | 0.411   |

PV – Plasma viscosity; RPV – Relative plasma viscosity; WBV – Whole blood viscosity; PT – Prothrombin Time; PTTK – Partial Thromboplastin Time with Kaolin.

Any condition that causes an imbalance between thrombogenic and anti-thrombogenic mechanisms predisposes humans to either an increased risk of bleeding or a hypercoagulable state. When blood clots develop within blood vessels, an individual is at increased risk of developing thromboembolic events such as deep vein thrombosis or pulmonary embolism. Parts of these venous blood clots can break off and migrate to the lungs, causing pulmonary embolism. Also, arterial clots can travel to other organs, such as the brain, heart, liver, and kidneys, cutting off blood flow to those organs and causing infarction.[7,8] The higher risk of cardiovascular disease among post-menopausal women due to possible coexisting lifestyle factors such as physical inactivity, high calorie/high-fat diet, and other stress conditions necessitated this study. Oestrogen treatment in post-menopausal women can influence blood clotting by increasing plasma fibrinogen and activity of some coagulation factors. Some have reported that
Oestrogen influences coagulation by increasing
gene transcription of blood clotting proteins. [16, 17] Early identification of haemorheological and
coaulation abnormalities may be helpful in the
prevention of cardiovascular complications and
the choice of a treatment regimen.

**Table III: Correlation analysis between haematological variables and age of participants**

| Variables                             | r   | p-value |
|---------------------------------------|-----|---------|
| Packed Cell Volume                    | -0.155 | 0.059   |
| Haemoglobin concentration             | -0.020 | 0.807   |
| Mean Corpuscular Volume               | 0.122  | 0.138   |
| Mean Corpuscular Haemoglobin          | 0.015  | 0.484   |
| Mean Corpuscular Haemoglobin
  Concentration                         | 0.015  | 0.853   |
| White Blood Cell count                | -0.008 | 0.925   |
| Lymphocytes                           | -0.005 | 0.953   |
| Neutrophils                           | -0.008 | 0.919   |
| Monocytes                             | -0.023 | 0.780   |
| Platelets                             | -0.010 | 0.908   |
| Plasma viscosity                      | -0.073 | 0.372   |
| Relative plasma viscosity             | 0.162  | 0.048   |
| Whole blood viscosity                 | 0.081  | 0.322   |
| Prothrombin time                      | -0.059 | 0.422   |
| PTTK                                  | 0.066  | 0.422   |
| Fibrinogen                            | -0.051 | 0.536   |

In the present study, no significant changes were
observed in PCV, Hb, MCV and MCH among
post-menopausal women compared with pre-
menopausal women. This finding is not
consistent with previous reports. [18] Menopausal
women were reported to have higher red cell
counts, haemoglobin concentrations,
haematocrits and increased MCV. The author
reported a progressive increase in haemoglobin
concentration from 40 years to 65 years of age.
That was attributed to the effects of the hormonal
environment at menopause and the cessation of
menstruation. A study reported that the
administration of oestrogen to post-menopausal
women caused an increased proliferation of
haematopoietic stem cells (HSCs), which
explained the higher blood counts in women
during their reproductive years. [19] No
significant alteration in red cell indices were
observed in the present study. This is presumably
due to differences in the nutritional status of the
subjects evaluated.

In the present study, significantly higher levels of
lymphocytes, neutrophils, platelet count, NLR
and PLR were observed among the post-
menopausal women than pre-menopausal
women. This finding aligns with a previous
study that reported that the increase in leucocyte count might be due to a rise in infections due to the changes associated with decreased levels of the hormone oestrogen, which include mucosal dryness and the change in the vaginal pH. [20] There was, however, no significant difference between the total WBC count, monocyte count and basophil count in the comparison groups.

A study reported an increase in plasma fibrinogen concentration and whole blood viscosity [21], but in the present study, the plasma fibrinogen concentration was not significantly different from that of the pre-menopausal women. The increase in blood viscosity may be attributed to a rise in the concentration of other plasma proteins other than fibrinogen and not due to PCV rise since the packed cell volume was not significantly altered between the study groups. The increase in blood viscosity coupled with changes in the vascular system previously reported may predispose post-menopausal women to cardiovascular diseases. The significantly lower PTTK without a concurrent change in PT or plasma fibrinogen concentration implies that the coagulation factor(s) of coagulation responsible for this belongs to the intrinsic coagulation pathway. [22] Previous authors reported significantly higher haematocrit and lower platelet count among post-menopausal women, a significantly lower APTT, PT and International Normalized Ratio (INR) in post-menopausal women than in the control group. This observation is not consistent in some ways with the findings from the present study. Whereas PTTK was significantly lower in this study, the PT was not significantly different between the study groups. The authors suggested that the higher values for PCV may enhance red blood cell aggregation, and the raised viscosity might aggravate the atherosclerotic risk. This study's significantly higher platelet count aligns with a previous study. [23] Elevated platelet count may increase the adhesiveness of platelets to the sub-endothelium tissues, and higher leakage of proteins through the vessel wall may increase atherosclerotic risk among post-menopausal women. Conversely, the observed higher platelet count is not consistent with the findings of other authors. [24, 25] Previous workers had reported that the significantly lower platelet count might be due to the low concentration of oestrogen in post-menopausal women.

The red cell indices, including PCV, haemoglobin concentration, MCV, MCH and MCHC, had no significant correlation with age. The total WBC count, lymphocytes count, neutrophil count, monocyte count also showed no significant correlation with age, whereas the relative plasma viscosity showed a significant correlation with age. This study showed no significant difference between PCV, haemoglobin concentration, MCV, MCH and MCHC of post-menopausal women and pre-menopausal women. This is in agreement with reports from a previous study. [22] However, a significantly higher level of PCV among post-menopausal women compared to pre-menopausal women had also been reported. [22]

**Conclusion**

Significant changes observed in some haemorheological and clotting profiles of post-menopausal women when compared to pre-menopausal women might be due to age and oestrogen deficiency. Identifying such changes at the right time may help to prevent vascular-related complications.

**Acknowledgement:** The authors appreciate the contributions of the physicians, nurses and medical laboratory scientists attached to the General Outpatient and Consultant Outpatient Departments of the University of Benin Teaching Hospital, Benin City,
Ebengho MI, et al.

Edo State, Nigeria, towards the completion of this study.

Authors’ Contributions: EMI and EMA conceived and designed the study while all the authors did data analysis and interpretation and drafted the manuscript. All the authors read and approved the final version of the manuscript.

Conflicts of Interest: None.

Funding: Self-funded.

Publication History: Submitted 14 January 2022; Accepted 15 March 2022.

References

1. Harlow SD, Gass M, Hall JE, Lobo R, Maki P, Rebar RW, et al. Executive summary of the Stages of Reproductive Aging Workshop +10: addressing the unfinished agenda of staging reproductive ageing. Fertil Steril 2012; 97: 398-406. https://doi.org/10.1097/gme.0b013e31824d8402

2. Thomas HN, Neal-Perry GS, Hess R. Female sexual function at midlife and beyond. Obstet Gynecol Clin North Am 2018; 45: 709-722. https://doi.org/10.1016/j.ogc.2018.07.013

3. Falkeborn M, Schairer C, Naessen T, Persson I. Risk of myocardial infarction after oophorectomy and hysterectomy. J Clin Epidemiol 2000; 53: 832-837. https://doi.org/10.1016/s0895-4356(00)00187-6

4. Lobo RA. Hormone Replacement therapy-Current thinking. Nat Rev Endocrinol 2017; 13: 220-231. https://doi.org/10.1038/nrendo.2016.164

5. McCarrey AC, Resnick SM. Post-menopausal hormone therapy and cognition. Horm Behav 2015; 74: 167-172. https://doi.org/10.1016/j.yhbeh.2015.04.018

6. Conway F. Health-related issues impacting older adults. J Women Aging 2019;31: 93-94.

7. Nkonde-Price C, Bender JR. Menopause and the Heart. Endocrinol Metab Clin North Am 2015; 44: 559-564.

8. Tarumi W, Shinohara K. The Effects of Essential oil on salivary oxytocin concentration in post-menopausal women. J Altern Complement Med 2020; 26: 226-230. https://doi.org/10.1089/acm.2019.0361

9. Nogueira IAL, da Cruz ÉJSN, Fontenele AMM, Figueiredo Neto JA1. Alterations in postmenopausal plasmatic lipidome. PLoS One 2018; 13: e0203027.

10. Hashemzadeh M, Romo R, Arreguin JM, Movahed MR. The effects of estrogen and hormone replacement therapy on cardiovascular systems. Future Cardiol 2021; 17: 347-353. https://doi.org/10.2217/fca-2020-0054

11. Gersh FL, O’Keefe JH, Lavie CJ. Post-menopausal hormone therapy for cardiovascular health: the evolving data. Heart 2021; 107: 1115-1122. https://doi.org/10.1136/heartjnl-2019-316323

12. US Preventive Services Task Force (USPSTF). Screening for osteoporosis in post-menopausal women: recommendations and rationale. Ann Intern Med 2002; 137: 526-528.

13. National Library of Medicine (NLM). Health consequences of tobacco use among women. In: AHCPR Archived Reports, Put Prevention into Practice and Minnesota Health Technology Advisory Committee. Reports of the Surgeon General. Women and Smoking. 2008. https://www.ncbi.nlm.nih.gov/books/NBK44312/ Accessed on 20 December 2021.

14. Elbilesy MA. Plasma viscosity and whole blood viscosity as diagnostic tools of blood abnormalities by using simple syringe method. Am J Haematol 2014; 89: 1-5. http://dx.doi.org/10.1002/ajh.23633

15. Claus A. Rapid Physiological Coagulation Method in Determination of Fibrinogen. Acta Haematologica 1957; 17: 237-246.

16. Kulkarni M and Hiremath S. Hematological changes in post-menopausal women. Natl J Physiol Pharm Pharmacol 2019; 9: 248-250.
17. Henes M, Hubner S. Hormone replacement therapy in peri- and postmenopause Internist (Berl) 2020; 61: 558-564. https://doi.org/10.1007/s00108-020-00789-x

18. Nakada D, Oguro H, Levi B, Ryan N, Kitano A, Saitoh Y, et al. Estrogen increases haematopoietic stem-cell self-renewal in females and during pregnancy. Nature 2014; 505: 555-558. https://doi.org/10.1038/nature12932.

19. Grays S. Tales from the Clinic. Post Reprod Health 2020; 26: 46-48. https://doi.org/10.1177/2053369120911552

20. Cowman J, Dunne E, Kenny D. Age-related changes in platelet function are more profound in women than in men. Sci Rep 2015; 5: 122355. https://doi.org/10.1038/srep12235

21. Bain BJ, Bates I, Laffan MA, Lewis SM. Dacie and Lewis Practical Haematology. 11th Edition. Elsevier Churchill Livingstone. New York. USA. 2012. p. 653.

22. Schneider HPG, Birkhauser M. Quality of Life in Climacteric women. Climacteric 2017; 20: 187-194. https://doi.org/10.1080/13697137.2017.1279599

23. Kofoed SC, Wittrup HH, Sillesen H, Nodestgaard BG. Fibrinogen predicts ischemic stroke and advanced atherosclerosis but not rupture-prone carotid plaques. Copenhagen City Euro-Heart J 2018; 24: 567-576.

24. Butkiewicz AM, Kemona H, Dymicka-Piekarska V, Matwicka-Karna J. Does menopause affect thrombocytopoiesis and platelet activation? Przegląd Lekarski 2006; 63: 1291-1293.

25. Lowe G, Rumley A, Norrie J, Ford I, Shepherd J, Cobbe S, et al. Blood rheology, cardiovascular risk factors and cardiovascular disease: the West of Scotland Coronary Prevention Study. J Thromb Haemost 2000; 84: 553-558.